| Autor: |
Maia, Israel S., Marcadenti, Aline, Veiga, Viviane C., Miranda, Tamiris A, Gomes, Samara P.C., Carollo, Mariana B.S., Negrelli, Karina L., Gomes, Jackeline O., Tramujas, Lucas, Abreu-Silva, Erlon O., Westphal, Glauco A., Fernandes, Ruthy P., Horta, Jacques G.A., Oliveira, Deborah C., Flato, Uri A.P., Paoliello, Ricardo C.R, Fernandes, Camilo, Zandonai, Cássio L., Coelho, Juliana C., Barros, Waldemar C., Lemos, Juliana C., Bolan, Renata S., Dutra, Marcela M., Gebara, Otavio C.E., Lopes, Ana T.A., Alencar Filho, Meton S., Arraes, Jussara A, Hamamoto, Victor A., Hernandes, Mauro E., Golin, Nicole A., Santos, Tiago M., Santos, Renato H.N., Damiani, Lucas P., Zampieri, Fernando G., Gesto, João, Machado, Flávia R., Rosa, Régis G., Azevedo, Luciano C.P., Avezum, Alvaro, Lopes, Renato D., Souza, Thiago M.L., Berwanger, Otávio, Cavalcanti, Alexandre B. |
| Zdroj: |
The Lancet Regional Health - Americas; 20230101, Issue: Preprints |
| Abstrakt: |
Repurposed drugs for treatment of new onset disease may be an effective therapeutic shortcut. We aimed to evaluate the efficacy of repurposed antivirals compared to placebo in lowering SARS-CoV2 viral load of COVID-19 patients. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
